• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 12, 2022 at 11:22: AM
via Bristol Myers Squibb's and Roche's immunotherapies have both failed to move the needle when used after surgery in early-stage kidney cancer. But the two companies’ setbacks aren’t necessarily a full relief for Merck’s rival drug Keytruda.

article source
 




Top Bottom
Back
Quote